Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK

International Journal of Clinical Practice

Volumn 63, Issue 7, 2009, Pages 1031-1040

  Prasad, S ^a   Arellano, J ^b   Steer, C ^c   Libretto, S E ^d  

^a CROMWELL HOSPITAL   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c VICTORIA HOSPITAL   (United Kingdom)

^d Sue Libretto Publications Consultant Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; METHYLPHENIDATE; PLACEBO; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ALGORITHM; AROUSAL; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DECREASED APPETITE; DISEASE COURSE; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ECONOMIC EVALUATION; EUROPE; GROUPS BY AGE; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; INSOMNIA; IRRITABILITY; JAUNDICE; LIVER TOXICITY; MONTE CARLO METHOD; MOOD CHANGE; OUTCOME ASSESSMENT; PARENT; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SUICIDAL IDEATION; SUICIDE ATTEMPT; TIC; TREATMENT RESPONSE; UNITED KINGDOM; VALIDITY; WEIGHT GAIN; WEIGHT REDUCTION; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROPYLAMINES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67650725906     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02090.x     Document Type: Article

References (54)

1. National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamphetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Review of Technology Appraisal 13. Technology Appraisal 98. http://www.nice.org.uk/download.aspx?o=TA098guidance (accessed May 2009).
2. Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005 90 (Suppl. 1 i2 7.
3. Matza LS, Prasad M, Clark Paramore L. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005 3 : 5.
4. Kutcher S, Aman M, Brooks SJ et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004 14 : 11 28. (Pubitemid 37495027)
5. Tettenborn M, Prasad S, Poole L et al. The provision and nature of ADHD services for children/adolescents in the UK - results from a nationwide survey. Clin Child Psychology Psychiatry 2008 13 : 287 304. (Pubitemid 351545782)
6. Dulcan M. Practice parameter for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactive disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1997 36 (10 Suppl. 85S 121S. (Pubitemid 27435161)
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). Washington, DC : American Psychiatric Association, 1994 : 78 85.
8. Green C, Chee K. Understanding ADHD - a Parent's Guide to Attention Deficit Hyperactive Disorder in Children. London : Vermillion publishing, 1997.
9. Spencer T, Biederman J, Wilens T et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996 35 : 409 32.
10. Spencer T, Biederman J, Wilens T et al. Adults with attention deficit-hyperactivity disorder: a controversial diagnosis. J Clin Psychiatry 1998 59 : 59 68. (Pubitemid 28317223)
11. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactive disorder with conduct, depressive, anxiety and other disorders. Am J Psychiatry 1991 148 : 564 77.
12. Barkley RA. Major life activity and health outcomes associated with attention deficit/hyperactivity disorder. J Clin Psychiatry 2002 63 : 10 5.
13. Wilens T, Biederman J, Spencer TJ et al. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. J Clin Psychiatry 1995 15 : 270 9.
14. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996 35 : 264 73.
15. Mannuzza S, Klein RG, Bessler A et al. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993 50 : 565 76.
16. Biederman J, Wilens TE, Mick E et al. Does attention-deficit hyperactive disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 1998 44 : 269 73.
17. Danckaerts M, Heptinstall E, Chadwick O et al. A natural history of hyperactivity and conduct problems: self-reported outcome. Eur Child Adolesc Psychiatry 2000 9 : 26 38. (Pubitemid 30193642)
18. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 1999 38 : 503 12.
19. Barbaresi WJ, Katusic SK, Colligan RC et al. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr 2007 28 : 265 73.
20. Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol 2000 40 : 379 88.
21. Banaschewski T, Coghill D, Santosh P et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adol Psychiatry 2006 15 : 476 95.
22. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry 2003 64 (Suppl. 11 3 8. (Pubitemid 37169642)
23. Wilens TE, Faraone SV, Biederman J et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature Pediatrics 2003 111 : 179 85.
24. Arnold LE. Methylphenidate vs amphetamine: comparative review. J Attention Disord 2000 3 : 200 11.
25. Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 2004 24 : 1020 36.
26. Michelson D, Buitelaar JK, Danckaerts M et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004 43 : 896 904. (Pubitemid 38808495)
27. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 108 : E83.
28. Prasad S, Harpin V, Poole L. A multi-centre, randomised, open-label study of atomoxetine with standard current therapy in UK children and adolescents with ADHD. Curr Med Res Opin 2007 23 : 379 94.
29. Kelsey DK, Sumner CR, Casat CD et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004 114 : e1 8.
30. Sangal RB, Owens J, Allen AJ et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006 29 : 1573 85.
31. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002 12 : 50 5.
32. Heil SH, Holmes HW, Bickel WK et al. Comparison of the subjective, placebo, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002 67 : 149 56.
33. Eli Lilly and Company. Strattera summary of product characteristics, 2008. http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid= 14482 (accessed May 2009).
34. Bangs ME, Jin L, Zhang S et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008 31 : 345 54 (in press).
35. Bangs ME, Tauscher-Wisniewski S, Polzer J et al. Meta-analysis of suicide-related events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008 47 : 209 18.
36. Buitelaar JK, Danckaerts M, Gillberg C et al. A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 2004 13 : 249 57.
37. Buitelaar JK, Michelson D, Danckaerts M et al. A randomized, double-blind study of continuation treatment for attention-deficit hyperactivity disorder after 1 year. Biol Psychiatry 2007 61 : 694 9.
38. Kratochvil CJ, Wilens TE, Greenhill LL et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 45 : 919 27.
39. Wilens TE, Newcorn JH, Kratochvil CJ et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 2006 149 : 112 9.
40. Scottish Intercollegiate Guidelines Network. SIGN No. 52. Attention Deficit and Hyperkinetic Disorders in Children and young People. A National Clinical Guideline, 2001. http://www.sign.ac.uk/guidelines/fulltext/52/index. html (accessed May 2009).
41. Cottrell S, Tilden D, Robinson P et al. A modelled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Val Health 2008 11 : 376 88.
42. Buxton MJ, Drummond MF, van Hout BA et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997 6 : 217 27.
43. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999 2 : 113 27.
44. McClure A, Prasad S, Poole L et al. Functional outcomes of children with attention deficit hyperactivity disorder in the UK. Arch Dis Child 2005 90 (Suppl. 11 A48.
45. Matza LS, Rentz AN, Secnik K et al. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behave Pediatr 2004 25 : 116 74.
46. Riley AW, Forrest CB, Starfield B et al. The parent report form of the CHIP-child edition. Reliability and validity. Med Care 2004 42 : 210 20.
47. Riley A, Chan K, Prasad S et al. A global measure of child health related quality of life: reliability and validity of the CHIP-CE global score. J Med Econ 2007 10 : 91 106.
48. Harter S. Manual for the Self-Perception Profile for Children. Denver, CO : University of Denver Press, 1985.
49. Perwien AR, Faries DE, Kratochvil CJ et al. Improvement in health-related quality of life in children with ADHD: an analysis of placebo-controlled studies of atomoxetine. J Dev Behave Pediatr 2004 25 : 264 71.
50. National Institute for clinical excellence. Guide to the methods of technology appraisal, 2004. http://www.nice.org.uk/aboutnice/howwework/ devnicetech/technologyappraisalprocessguides/ guidetothemethodsoftechnologyappraisal.jsp (accessed May 2009).
51. Scottish Medicines Consortium. Guidance to manufacturers. Economic questions and answers. http://www.scottishmedicines.org.uk (accessed May 2009).
52. Tom E, Schulman KA. Mathematical models in decision analysis. Infect Control Hosp Epidemiol 1997 18 : 65 73. (Pubitemid 127469920)
53. Secnik K, Matza KS, Cottrell S et al. Health state utilities for childhood ADHD based on parent preferences in the United Kingdom. Med Decis Making 2005 25 : 56 70.
54. Kobelt G. Health Economics: an Introduction to Economic Evaluation. London : Office of Health Economics, 2002.